The Occurence of Inflammation and Oxidative Stress in Lung Diseases
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.
The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD
| Condition |
|---|
|
Interstitial Lung Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis COPD |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants |
blood samples were collected
| Enrollment: | 76 |
| Study Start Date: | September 2005 |
| Study Completion Date: | June 2006 |
| Groups/Cohorts |
|---|
|
sarcoidosis
21 onset patients, non-treated
|
|
IPF
15 IPF patients, partially treated
|
|
COPD
15 COPD patients within 24 hours after their last exacerbation
|
|
controls
25 healthy controls, matched for age and gender
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
lung patients visiting the out-patient clinic of the Academic Hospital Maastricht
Inclusion Criteria:
- clinical diagnosis of pulmonary sarcoidosis, IPF or COPD
- no treatment for sarcoidosis
- last exacerbation not more than 24 hours ago for COPD
- healthy controls
- no smoking for sarcoidosis and IPF
Exclusion Criteria:
- pregnancy
- use of vitamins or food supplements
- clinical diagnosis (and treatment) of other diseases
- symptoms of sarcoidosis in other organs besides the lung
Contacts and Locations| Netherlands | |
| Maastricht University | |
| Maastricht, Netherlands, 6224 LH | |
| Study Chair: | Aalt Bast, PhD | Maastricht University |
| Principal Investigator: | Agnes W Boots, PhD | Maastricht University |
| Study Director: | Guido R Haenen, PhD | Maastricht University |
More Information
No publications provided
| Responsible Party: | Dr. A.W. Boots, Maastricht University |
| ClinicalTrials.gov Identifier: | NCT00512967 History of Changes |
| Other Study ID Numbers: | MEC 03-112 |
| Study First Received: | July 19, 2007 |
| Last Updated: | February 25, 2008 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
Keywords provided by Maastricht University Medical Center:
|
oxidative stress antioxidants inflammation quercetin |
Additional relevant MeSH terms:
|
Fibrosis Inflammation Lung Diseases Pulmonary Disease, Chronic Obstructive Pulmonary Fibrosis Lung Diseases, Interstitial Sarcoidosis Sarcoidosis, Pulmonary Idiopathic Pulmonary Fibrosis Pathologic Processes |
Respiratory Tract Diseases Lung Diseases, Obstructive Lymphoproliferative Disorders Lymphatic Diseases Idiopathic Interstitial Pneumonias Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013